Merck (MRK) 44th Annual J.P. Morgan Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
44th Annual J.P. Morgan Healthcare Conference summary
16 Jan, 2026Strategic positioning and growth pillars
Positioned for growth in innovation-driven and secular markets, focusing on Process Solutions, rare diseases, and Semiconductor Solutions as key growth drivers.
Multi-industry model and diversified global footprint provide resilience amid geopolitical changes.
M&A and disciplined portfolio management remain central, with recent acquisitions like SpringWorks and divestments such as Surface Solutions, supported by strong cash generation.
Three sectors—Life Science, Healthcare, and Electronics—target highly innovative end-markets.
Key growth drivers expected to contribute up to 80% of future growth.
Sector performance and outlook
Life Science sector reorganized for customer-centricity, with three go-to-market models: Process Solutions, Advanced Solutions, and Discovery Solutions, and a new structure effective January 2026.
Process Solutions expected to grow 9%-10% midterm, driven by demand for monoclonal antibodies and novel modalities.
Healthcare focuses on rare diseases, oncology, and fertility, with new launches and pipeline advancements.
Electronics sector leverages semiconductor and optronics solutions, with AI and advanced nodes driving mid-term growth.
Advanced Solutions and Discovery Solutions forecasted for mid- to high-single-digit and low-single-digit growth, respectively.
Pipeline, innovation, and M&A
Rare disease portfolio includes Ogsiveo, Gomekli, and pimicotinib, with combined peak sales potential of €2.5 billion and multiple launches planned through 2027.
Pipeline replenishment strategy emphasizes external innovation, aiming for 50% of new launches from outside sources.
Ongoing openness to in-licensing and bolt-on M&A, especially in rare diseases.
Electronics sector, especially Semiconductor Solutions, benefits from AI-driven demand and advanced packaging, with over 50% of the portfolio in advanced nodes.
M&A strategy remains focused on innovation-driven businesses, using a string of pearls approach for targeted acquisitions.
Latest events from Merck
- 2025 delivered resilient organic growth and margins; 2026 guidance reflects FX and regulatory risks.MRK
Q4 202525 Mar 2026 - 2025 guidance met with stable sales and EBITDA; 2026 outlook cautious amid FX and Mavenclad risks.MRK
Q4 2025 (Media)5 Mar 2026 - Q2 2024 growth led by Healthcare and Electronics, with raised guidance for the full year.MRK
Q2 202412 Feb 2026 - Q3 2024 delivered strong organic growth, margin expansion, and confirmed 2024 guidance.MRK
Q3 202412 Feb 2026 - Q1 2025 delivered solid growth and margin expansion, with guidance reflecting macro headwinds.MRK
Q1 202512 Feb 2026 - Life Science and Healthcare growth drove Q2 2025 organic gains, offsetting Electronics and FX headwinds.MRK
Q2 202512 Feb 2026 - Q3 2025 saw robust organic growth, margin gains, and strategic expansion amid FX risks.MRK
Q3 202512 Feb 2026 - Promising DDR and ADC assets advance in clinic, with strong external partnerships and biomarker focus.MRK
Investor Update31 Jan 2026 - All sectors on track for sustainable growth, margin expansion, and ESG leadership.MRK
CMD 202419 Jan 2026